4HG Stock Overview
A med-tech company, manufactures and sells in-vitro diagnostic analyzers and reagents.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Qlife Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.0001 |
| 52 Week High | kr0.02 |
| 52 Week Low | kr0.0001 |
| Beta | 0.69 |
| 11 Month Change | 0% |
| 3 Month Change | -88.89% |
| 1 Year Change | 0% |
| 33 Year Change | -100.00% |
| 5 Year Change | n/a |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4HG | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.6% | 0.9% |
| 1Y | 0% | 0.3% | 4.2% |
Return vs Industry: 4HG matched the German Medical Equipment industry which returned 0.3% over the past year.
Return vs Market: 4HG underperformed the German Market which returned 4.2% over the past year.
Price Volatility
| 4HG volatility | |
|---|---|
| 4HG Average Weekly Movement | 117.6% |
| Medical Equipment Industry Average Movement | 4.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 4HG's share price has been volatile over the past 3 months.
Volatility Over Time: 4HG's weekly volatility has decreased from 1190% to 118% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 11 | Thomas Warthoe | www.qlifeholding.com |
Qlife Holding AB (publ), a med-tech company, manufactures and sells in-vitro diagnostic analyzers and reagents. The company offers Egoo Health Platform, an integrated platform with a measuring instrument with disposable capsules and software, where each capsule contains a test for a specific biomarker or virus.
Qlife Holding AB (publ) Fundamentals Summary
| 4HG fundamental statistics | |
|---|---|
| Market cap | €487.54k |
| Earnings (TTM) | -€13.45m |
| Revenue (TTM) | €10.74k |
45.4x
P/S Ratio0.0x
P/E RatioIs 4HG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4HG income statement (TTM) | |
|---|---|
| Revenue | kr121.00k |
| Cost of Revenue | kr5.17m |
| Gross Profit | -kr5.05m |
| Other Expenses | kr146.48m |
| Earnings | -kr151.53m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 15, 2024
| Earnings per share (EPS) | -0.041 |
| Gross Margin | -4,170.25% |
| Net Profit Margin | -125,228.93% |
| Debt/Equity Ratio | -27.2% |
How did 4HG perform over the long term?
See historical performance and comparison